000144788 001__ 144788
000144788 005__ 20240229112637.0
000144788 0247_ $$2doi$$a10.1016/j.canep.2019.101596
000144788 0247_ $$2pmid$$apmid:31520938
000144788 0247_ $$2ISSN$$a1877-7821
000144788 0247_ $$2ISSN$$a1877-783X
000144788 037__ $$aDKFZ-2019-02220
000144788 041__ $$aeng
000144788 082__ $$a610
000144788 1001_ $$aKollár, Attila$$b0
000144788 245__ $$aIncidence, mortality, and survival trends of soft tissue and bone sarcoma in Switzerland between 1996 and 2015.
000144788 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2019
000144788 3367_ $$2DRIVER$$aarticle
000144788 3367_ $$2DataCite$$aOutput Types/Journal article
000144788 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1575968399_1465
000144788 3367_ $$2BibTeX$$aARTICLE
000144788 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144788 3367_ $$00$$2EndNote$$aJournal Article
000144788 520__ $$aResearch on soft-tissue sarcoma (STS) and bone sarcoma (BS) is increasingly in the focus of physicians and pharmaceutical companies. Expanding knowledge has improved the management of sarcoma and possibly survival. Here we provide the first population-based data on time trends of incidence, mortality, and survival of STS and BS diagnosed in Switzerland between 1996 and 2015.We performed a retrospective registry study with data from the National Institute for Cancer Epidemiology and Registration (NICER) database in Switzerland between 1996 and 2015.We identified 5384 STS patients and 940 BS patients. The three most common STS subtypes were undifferentiated/unclassified sarcoma (22.3%), liposarcoma (20.6%) and leiomyosarcoma (20.6%). Chondrosarcoma, osteosarcoma and Ewing sarcoma represented 40.4%, 27.0% and 15.2% of the BS group, respectively. The age-standardized incidence and mortality rates in 2011-2015 were 4.43 and 1.42 per 100,000 person-years for STS, and 0.91 and 0.42 for BS. Age-standardized incidence of STS in males was significantly higher during 1996-2000 than during 2001-2015; however, mortality rates did not change significantly over time. Five-year relative survival (RS) for STS improved significantly from 56.4% (95%CI 52.9-59.7 for 1996-2001) to 61.6% (95%CI 58.6-64.4 for 2011-2015) (p = 0.025). No improvement in 5-year RS for BS could be observed (RS 1996-2000: 69.6%, 95%CI 61.2-76.6; RS 2011-2015: 73.1%, 95%CI 66.6-78.6; p = 0.479).Incidence rates of STS and BS have been stable since 2001. The longer RS in STS can be attributed to advances in sarcoma patient management.
000144788 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000144788 588__ $$aDataset connected to CrossRef, PubMed,
000144788 7001_ $$aRothermundt, Christian$$b1
000144788 7001_ $$aKlenke, Frank$$b2
000144788 7001_ $$aBode, Beata$$b3
000144788 7001_ $$aBaumhoer, Daniel$$b4
000144788 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b5$$udkfz
000144788 7001_ $$aFeller, Anita$$b6
000144788 7001_ $$aGroup, NICER Working$$b7$$eCollaboration Author
000144788 773__ $$0PERI:(DE-600)2498032-8$$a10.1016/j.canep.2019.101596$$gVol. 63, p. 101596 -$$p101596$$tCancer epidemiology$$v63$$x1877-7821$$y2019
000144788 909CO $$ooai:inrepo02.dkfz.de:144788$$pVDB
000144788 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000144788 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000144788 9141_ $$y2019
000144788 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144788 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144788 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEMIOL : 2017
000144788 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144788 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000144788 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000144788 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144788 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144788 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144788 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000144788 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000144788 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000144788 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lCancer Survivorship$$x0
000144788 980__ $$ajournal
000144788 980__ $$aVDB
000144788 980__ $$aI:(DE-He78)C071-20160331
000144788 980__ $$aUNRESTRICTED